Monthly Archives: March 2018

Meet Daniel Taub; A Renowned International Lawyer

While speaking to The Independent, Daniel Taub said that the Geneva Accord that was signed would not help in containing threats posed by Iran. He also added that the Geneva Accord could not slow the acquisition of nuclear weapons by Iran. Read more: Daniel Taub | Wikipedia and Daniel Taub | LinkedIn

In 2013, a team of Israeli security officials held talks with officials from America in Washington over ways of creating partnerships that can help to reduce security risks. In the meeting, Taub proposed the cooperation between Israel and Sunni countries such as Saudi Arabia.

Mr. Taub said that there were numerous worries about Iran’s nuclear weapons. Daniel Taub noted that some of the areas that were significantly affected by Iran’s nuclear missions include Gaza, Beirut, and Damascus among others. Taub said that there was the need for countries to put their differences aside and collaborate towards ensuring security.

Daniel Taub stated that changes were happening around Israel that led to countries changing their approach towards security measures. Taub also reported that there was the need for sharing between Israel and its western allies. The deal signed by Iran signified one of the most diplomatic agreements between Israel and Islamic countries. Since 1979, Israel and Islamic countries have never agreed on important issues of ensuring security.

Mr. Hague reported that Iran’s decision was an important step towards ensuring security within the Islamic republic. Hague added that Iran’s new approach would boost security across the world.

However, Israel did not support Iran’s take on the issue. Mr. Taub noted that signing a deal with Iran does not guarantee through preventing Iran from acquiring bombs and other weapons. Learn more about Daniel Taub: and

Daniel Taub is a renowned international lawyer and a diplomat. Some of the articles he has written have been included in the Daily Telegraph, the Guardian, and the Times among others.

Taub is also recognized for writing Parasha Diplomatic which gives insights on the Bible. Additionally, Mr. Taub is the chief scriptwriter of HeChatzer which is a well-known drama series in Israel.

Taub moved to Israel to work as a lawyer on Intellectual property. During the Madrid Peace Conference, Israel wanted to make peaceful negotiations with neighboring countries. Since Taub had pursued international law, he saw it as an excellent opportunity to work in Israeli foreign ministry.

Since he joined the department, he had maintained his position for more than two decades. Daniel tries to keep a balance while working to ensure business cooperation, intelligence sharing, and academic cooperation among other major concerns.


Seattle Genetics has been at the forefront of cancer research in America for over 20 years. The company which specializes in developing drugs for targeted cancer therapy has had developed 15 patents since its inception. One of the companies breakthrough developments, ADCetris, was the first ever antibody drug conjugate, ADC, to be developed, and also the first of its kind to receive FDA approval. ADCetris is now approved for use in over 65 countries around the world.

Seattle Genetics has achieved this under the able leadership of its founder and CEO, Clay Siegall. Driven by a strong desire to help ease the burden and pain of cancer patients, Clay Siegall believes that older methods of cancer treatment such as chemotherapy are slowly being edged out by targeted therapies which are more efficient and tolerable for patients. Having watched his father undergo a brutal cancer treatment method and suffer from its accompanying side effects in his youth, Clay Siegall made a vow to help find a better, more favorable method that would help ease the pain on patients.

Clay Siegall started his career at the Bristol-Myers Squibb Pharmaceutical research Institute as a Senior Research Investigator before rising to the position of Principal Scientist. The PhD in Genetics graduate from the George Washington University then went on to join the National cancer Institute as a Biotechnology Fellow and Staff Fellow. He has published over 70 articles where he shares his scientific knowledge with other researchers and the community at large.

Other than his exemplary leadership in research and development of new therapies for the treatment of cancer, Clay Siegall also leads Seattle Genetics in fundraising for its much needed capital for their research activities. Including their initial public offering in 2001, Seattle Genetics has raised over $1.2 billion in public and private financing. He also serves on the Board of Directors for Alder Bio-pharmaceuticals, Washington Roundtable and Ultragenyx Pharmaceuticals respectively.

Desiree Perez and Other Women Innovating the Music Industry

In a world that was once dominated by the older male demographic, we are now seeing a shift in both age and gender. Every year, more and more women are becoming very successful in the entertainment music industry.

Desiree Perez, age 47, has been in the music industry longer than almost all other current female executives. Perez has a list of talent association far too long to be listed but include Jay-Z, Beyonce and Rihanna.

Perez is the COO of Roc Nation Records and has worked on deals pertaining to tours, sponsorships, events and album releases. At Roc Nation, she is able to do the work that would normally take a half-dozen people because she is experienced and has a great working relationship with all her associates.

One of her most recent accomplishments is a deal with Sprint. Desiree Perez was able to negotiate a deal with Sprint that not only included a 200 million dollar investment in Tidal, Roc Nation’s Spotify competitor, but also enabled subscribers of Sprint to download Jay-Z’s “4:44” free of charge.

The current album tour for “4:44” has grossed 21 percent more than the previous album tour in 2013.


Roc Nation was created by Shawn “Jay-Z” Carter in 2008 as a replacement for his defunct record label Roc-A-Fella Records. Carter wanted a new brand for his new talent, so he started from the ground up. Perez was hired as COO less than a year after its creation.

The record label is responsible for contemporary classics like “My Beautiful Dark Twisted Fantasy” by Kanye West, “Lemonade” by Beyonce and “Blueprint 3” by Jay-Z.

Desiree Perez Info:

TMS Health Solutions Leads the Way with Innovative Therapy for Treatment-Resistant Depression

Seeking treatment for depression is not easy, especially if past treatments failed. More than 16 million Americans will suffer from Major Depressive Disorder once in their lives. Of those seeking treatment, up to 40 percent may not get relief from conventional treatments and can remain mired in the fear and pain of their disease, too discouraged to try again. This type of Treatment-Resistant Depression requires comprehensive care and sufferers may benefit from a new therapy called Transmagnetic Cranial Stimulation (TMS), one of several cutting-edge treatment options offered by California-based TMS Health Solutions.

Major Depressive Disorder, also known as clinical depression, is a serious illness that is much more than the occasional low mood everyone experiences at some time in their lives. Characterized by feelings of sadness, emptiness or hopelessness for most days over a two week period or more, patients often report fatigue, changes in appetite or sleep, loss of interest in activities, and difficulty concentrating among other symptoms.

First-line treatment for depression utilizes medication and psychotherapy, but when two or more attempts with have failed, patients can be left with ongoing symptoms that can cause devastating effects in their lives. This type of Treatment-Resistant Depression may be successfully treated with alternative therapies.

TMS Health Solutions specializes in Treatment-Resistant Depression. With offices in the San Francisco and surrounding areas, they offer comprehensive mental health services including psychotherapy and medication management and are Northern California’s leading provider of TMS therapy.

TMS therapy is a non-invasive, FDA-approved treatment that works by using a simple coil applied to the scalp to send magnetic pulses to the areas of the brain that control mood. Unlike Electroconvulsive Therapy (ECT), TMS therapy requires no anesthesia and only minimal side effects such as headache or scalp discomfort are usually reported.

A course of TMS therapy consists of daily 30 to 60 minute treatments over a four to eight week period depending on the individual’s response and most people are able to return to work or other activities immediately after a session. TMS therapy is covered by most major insurers and the TMS Health Solutions team helps patients navigate their coverage.

The expert physicians at TMS Health Solutions recognize that all patients are individuals and no single approach is best for everyone, but if treatment for persistent depression has failed, a full and integrated approach may hold the key to success.